**S1 Table.** Study Subjects

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Subject** | **Age** | **Ethnicity** | **Sex** | **Diagnosis** | **Antibiotics** | **Pathogen** |
| **Subjects on antibiotics** |  |  |
| ELA1 | 73 | Caucasian | Male | Bone infection | Cefazolin and trimethoprim/sulfamethaxole | MSSAa |
| ELA2 | 66 | Caucasian | Male | Bone infection | Vancomycin and meropenem | MRSAb and Pseudomonas aeruginosa |
| ELA3 | 62 | Caucasian | Male | Bone infection | Vancomycin, daptomycin and ceftazidime | Coagulase negative staphylococcus |
| ELA33 | 69 | Caucasian | Female | Brain abscess | Vancomycin and rifampin | MRSA and Enterococcus faecalis |
|  |  |  |
| **Control subjects** |  |  |
| ELA4 | 25 | Asian | Male | Healthy | None | None |
| ELA7 | 25 | Caucasian | Male | Healthy | None | None |
| ELA8 | 51 | Latino | Female | Healthy | None | None |
| ELA9 | 34 | African-American | Male | Healthy | None | None |
| ELA100 | 32 | Asian | Female | Healthy | None | None |

aMethicillin Sensitive Staphylococcus aureus

bMethicillin Resistant Staphylococcus aureus